<SUBMISSION>
<ACCESSION-NUMBER>0000351721-02-000038
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>1
<PERIOD>20021105
<ITEMS>2
<FILING-DATE>20021105
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>ADVANCED NEUROMODULATION SYSTEMS INC
<CIK>0000351721
<ASSIGNED-SIC>3841
<IRS-NUMBER>751646002
<STATE-OF-INCORPORATION>TX
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>000-10521
<FILM-NUMBER>02809655
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>6501 WINDCREST DRIVE SUITE 100
<CITY>PLANO
<STATE>TX
<ZIP>75024
<PHONE>9723098000
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>6501 WINDCREST DRIVE SUITE 100
<CITY>PLANO
<STATE>TX
<ZIP>75024
</MAIL-ADDRESS>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>QUEST MEDICAL INC
<DATE-CHANGED>19920703
</FORMER-COMPANY>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>k8nov02.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>ADVANCED NEUROMODULATION SYSTEMS, INC. FORM 8-K</TITLE>
</HEAD>
<BODY>
<H1 ALIGN=CENTER><FONT SIZE=3>SECURITIES AND EXCHANGE COMMISSION</FONT></H1>
<H1 ALIGN=CENTER><FONT SIZE=3>Washington, D.C. 20549</FONT></H1>
<HR SIZE=1 WIDTH=15% ALIGN=CENTER>
<H1 ALIGN=CENTER><FONT SIZE=4>FORM 8-K</FONT></H1>
<HR SIZE=1 WIDTH=15% ALIGN=CENTER>
<H1 ALIGN=CENTER><FONT SIZE=3>CURRENT REPORT<BR>PURSUANT TO SECTION 13 OR 15(d)
OF THE<BR>SECURITIES EXCHANGE ACT OF 1934</FONT></H1>
<H1 ALIGN=CENTER><FONT SIZE=3>Date of report (Date of earliest event reported):
<BR>November 5, 2002 (November 4, 2002)</FONT></H1>

<HR SIZE=1 WIDTH=15% ALIGN=CENTER>
<P ALIGN=CENTER><FONT SIZE=3>Commission file number 0-10521</FONT></P>
<H1 ALIGN=CENTER><FONT SIZE=4>ADVANCED NEUROMODULATION SYSTEMS, INC.</FONT></H1>
<P ALIGN=CENTER><FONT SIZE=3>Incorporated pursuant to the Laws of the State of
Texas</FONT></P>
<HR SIZE=1 WIDTH=15% ALIGN=CENTER>
<P ALIGN=CENTER><FONT SIZE=3>Internal Revenue Service &#151; Employer
Identification No. 75-1646002</FONT></P>
<P ALIGN=CENTER><FONT SIZE=3>6501 Windcrest Drive, Plano, Texas 75024</FONT></P>
<P ALIGN=CENTER><FONT SIZE=3>(972) 309-8000</FONT></P>
<HR>

<PAGE>
<P><B>Item 5.&nbsp;&nbsp;Other Events</B></P>
<P>On November 4, 2002, we entered into an agreement to acquire MicroNet
Medical, Inc., a Minnesota corporation ("MicroNet"), through a merger of
MicroNet Acquisition Corp., a Delaware corporation and our wholly-owned
subsidiary, with and into MicroNet (the "Merger"). Upon the closing of the
Merger, which is subject to MicroNet shareholder approval and other customary
conditions, we will pay the MicroNet shareholders $500,000 in cash and a number
of shares of our Common Stock with a value of $5,233,000 based on the average
trading price of our Common Stock for the 30 days preceding closing. If certain
product, regulatory approval, and sales milestones are met over the next five
years, we could pay the Micronet shareholders an additional number of shares of
our Common Stock with an aggregate value of $9,000,000. For additional
information, reference is made to the press release attached hereto as Exhibit
99.1.</P>
<P><B>Item 7.&nbsp;&nbsp;Financial Statements, Pro Forma Financial Information
and Exhibits.</B></P>
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0>
<TR>
<TD WIDTH=7% ALIGN=LEFT>(c)</TD>
<TD WIDTH=93% ALIGN=LEFT>Exhibits</TD></TR>
<TR><TD>&nbsp;</TD><TD></TD></TR>
<TR>
<TD VALIGN=TOP>99.1</TD>
<TD>Press Release dated November 4, 2002</TD></TR></TABLE>
<HR>

<PAGE>
<H1 ALIGN=CENTER><FONT SIZE=3>SIGNATURES</FONT></H1>
<P><FONT SIZE=3>Pursuant to the requirements of the Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.</FONT></P><TABLE>
<TR>
<TD WIDTH=40%></TD>
<TD WIDTH=60%>ADVANCED NEUROMODULATION SYSTEMS, INC.<BR><BR><BR></TD></TR>
<TR>
<TD WIDTH=40%></TD>
<TD WIDTH=60%>By:&nbsp;<U>/s/ F. Robert Merrill III</U></TD></TR>
<TR>
<TD WIDTH=40%>Date: November 5, 2002</TD>
<TD WIDTH=60%>Name: F. Robert Merrill III</TD></TR>
<TR>
<TD WIDTH=40%></TD>
<TD WIDTH=60%>Title: Executive Vice President,Finance</TD></TR>
<TR>
<TD WIDTH=40%></TD>
<TD WIDTH=60%>Chief Financial Officer and Treasurer</TD></TR></TABLE>
<HR>

<PAGE>
<P ALIGN=RIGHT><B><U>Exhibit 99.1</U></B></P>
<P ALIGN=CENTER><U>PRESS RELEASE</U></P>
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0>
<TR>
<TD WIDTH=60% ALIGN=LEFT>[Graphic omitted]</TD>
<TD WIDTH=40% ALIGN=RIGHT>FOR IMMEDIATE RELEASE</TD></TR>
<TR>
<TD>&nbsp;</TD><TD></TD></TR>
<TR>
<TD WIDTH=60% ALIGN=LEFT>Agency Contact:</TD>
<TD WIDTH=40% ALIGN=RIGHT>Company Contact:</TD></TR>
<TR>
<TD>Neil Berkman Associates</TD>
<TD ALIGN=RIGHT>Chris Chavez</TD></TR>
<TR>
<TD>(310) 277-5162</TD>
<TD ALIGN=RIGHT>President &amp; CEO</TD></TR>
<TR>
<TD>info@BerkmanAssociates.com</TD>
<TD ALIGN=RIGHT>(972) 309-8000</TD></TR></TABLE>
<P ALIGN=CENTER><B>Advanced Neuromodulation Systems To Acquire Micronet Medical
</B></P>
<P>DALLAS, TEXAS, November 5, 2002 -- Advanced Neuromodulation Systems, Inc.
(ANS, NASDAQ:ANSI) announced today it has agreed to acquire Micronet Medical,
Inc. (Micronet), a developer of medical devices based on proprietary micro-lead
technology. Privately held Micronet is based in St. Paul, Minnesota.<P>
<P>"Micronet is an important technology acquisition for ANS. Micronet has
developed a line of very thin and steerable spinal cord stimulation (SCS) leads
called Axxess&#153;. Axxess leads are the smallest neurostimulation leads on the
market, which we believe offers compelling advantages in certain applications.
Its unique design makes it highly maneuverable for implanters resulting in
faster and more accurate placement," commented Scott Drees, ANS' executive vice
president, sales and marketing.</P>
<HR>

<PAGE>
<P>Under the terms of the transaction, which will be structured as a merger, ANS
will acquire only Micronet's proprietary technology and certain associated
tangible assets. Micronet's operations, other tangible assets, certain
liabilities and certain employees will become part of a separate unaffiliated
company. The unaffiliated company will continue to serve Micronet's OEM and
sterilization customers without interruption. ANS will assume no material debt,
liabilities, or overhead in the transaction.</P>
<P>Upon closing, which is subject to Micronet shareholder approval and other
customary conditions, ANS will pay Micronet shareholders $500,000 in cash and a
number of shares of ANS Common Stock with a value of $5,233,000, based on the
average trading price for the 30 days preceding closing. In addition, if certain
product, regulatory approval and sales milestones are met, ANS could pay
Micronet shareholders an additional number of shares of Common Stock with an
aggregate value of up to $9 million. Important milestone deadlines occur six,
twelve and eighteen months following the closing for product milestone purposes,
while other milestones depend on the receipt of regulatory approvals and meeting
an aggregate sales milestone. All milestones must be met within the next four to
five years, depending on the milestone. The transaction is expected to close by
the end of 2002.</P>
<P>"We intentionally structured this transaction to match the price paid to the
value ultimately received from the technology," said Chris Chavez, president and
chief executive officer of ANS. "Acquiring the Micronet technology will broaden
and strengthen ANS' neurostimulation platform technologies."</P>
<HR>

<PAGE>
<P>In July 2001, Micronet received 510(k) clearance from the FDA to market its
Axxess spinal cord stimulation leads. "We will need to adapt the Axxess leads so
they are compatible with our Renew&reg; radio frequency (RF) systems and our
family of Genesis&#153; implantable pulse generator (IPG) systems, which will
take some time. The milestones we have developed should enable us to begin
marketing SCS leads utilizing the Micronet technology in the third quarter of
2003. In addition, projects and deliverables have been designed to produce leads
for other applications, including specialty leads for deep brain stimulation
(DBS). The acquisition of Micronet is an extension of ANS' strategy to develop
the broadest and most advanced lines of neuromodulation technologies to serve
our customers' expanding needs," Chavez said.</P>
<P>"Coupled with ANS' growing family of spinal cord stimulation systems, we
believe the Micronet lead technology will uniquely position us to further
penetrate the large and growing SCS market," Chavez added. ANS recently
announced the FDA has approved, Genesis<I>XP</I>&#153;, an enhanced version of
its Genesis IPG system. Genesis<I>XP</I> offers more than two times the battery
capacity of Genesis, resulting in enhanced longevity and, therefore, fewer
battery replacements.</P>
<P>"We expect a modest revenue contribution and no impact on earnings per share
from this acquisition in 2003. What is most important is we believe this
transaction will assist us in achieving the continued substantial growth we have
targeted for 2003 and beyond," Chavez concluded.</P>
<P><B>About Advanced Neuromodulation Systems</B></P>
<P>Advanced Neuromodulation Systems designs, develops, manufactures and markets
implantable systems used to manage chronic intractable pain and other disorders
of the central nervous system. Forbes magazine recently recognized ANS as one of
America's 200 Best Small Companies. Additional information is available at
<U>www.ans-medical.com.</U></P>
<P><I>"Safe harbor" statement under the Private Securities Litigation Reform Act
of 1995:</I></P>
<P><I>Statements contained in this press release that are not based on
historical facts are "forward-looking statements." Terms such as "plan,"
"should," "would," "anticipate," "believe," "intend," "estimate," "expect,"
"predict," and similar expressions are intended to identify forward-looking
statements. Such statements are by nature subject to uncertainties and risks,
including but not limited to: market acceptance of the Micronet lead; completion
of new products in an efficient and timely manner; obtaining regulatory
approvals on a timely and cost-efficient basis; the satisfactory completion of
clinical trials and/or market tests; the adequacy, acceptability and timeliness
of component supply; the accounting determination of the value of the intangible
assets acquired, the resolution of other accounting matters and the resulting
impact on financial statement presentation; reimbursement; competition; and
other risks detailed from time to time in the Company's SEC filings.
Consequently, if such management assumptions prove to be incorrect or such risks
or uncertainties materialize, anticipated results could differ materially from
those forecast in forward-looking statements.</I></P>
</BODY>
</HTML>

</TEXT>
</DOCUMENT>
</SUBMISSION>
